Ravulizumab administration for relapse prevention in atypical hemolytic uremic syndrome with a CFH variant: A case report.

Atypical hemolytic uremic syndrome (aHUS) is a rare cause of thrombotic microangiopathy (TMA). When aHUS cannot be excluded, diagnostic treatment with anti-C5 antibody agents should be considered. We report a patient with a novel heterozygous complement factor H (CFH) variant, p.Glu1198Asp (c.3594A>T), who received ravulizumab three months after disease onset. Ravulizumab was administered for relapse prevention in the chronic phase, and no recurrence of thrombotic microangiopathy was observed during the follow-up.